Advanced Prostate Cancer clinical trials

Explore recruiting advanced prostate cancer clinical trials.

Recruiting advanced prostate cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Prostate Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy

Austria, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase I/II Study of Neoadjuvant, Intra-arterial Administration of [177Lu]Lu-PSMA-617 in Subjects with High-risk, Localised or Locally Advanced Prostate Cancer who are Candidates for Radical Prostatectomy (LUPUS)

Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

SUrGery with or without dARolutamide in high-risk and/or locally advanced prostate cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy – lipid metabolism as a novel biomarker to predict prostate cancer progression – phase 3, double-blind randomized clinical trial FinnProstata XV. ESTO2.

Denmark, Finland, Norway, Estonia

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, randomized, open-label, dose-finding study of Debio 4228, an extended-release formulation of gonadotropin-releasing hormone antagonist in participants with advanced prostate cancer

France, Belgium, Spain, Poland, Bulgaria, Italy +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy

Belgium, Czechia, Sweden, Romania, Spain, Germany +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Advanced Prostate Cancer trials by city

Advanced Prostate Cancer in Toronto Advanced Prostate Cancer in Vancouver Advanced Prostate Cancer in Montreal Advanced Prostate Cancer in Calgary Advanced Prostate Cancer in Edmonton Advanced Prostate Cancer in Ottawa Advanced Prostate Cancer in Winnipeg Advanced Prostate Cancer in Quebec City Advanced Prostate Cancer in Hamilton Advanced Prostate Cancer in Kitchener Advanced Prostate Cancer in London Advanced Prostate Cancer in Halifax Advanced Prostate Cancer in New York Advanced Prostate Cancer in Los Angeles Advanced Prostate Cancer in Chicago Advanced Prostate Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease